VIROLOGICA SINICA

Electronic Supplementary Material

KIR2DL2/C1 Is a Risk Factor for Chronic Infection and Associated With Non-Response to PEG-IFN and RBV Combination Therapy in Hepatitis C Virus Genotype 1b Patients in China

Song Hu[1], Fahu Yuan[1], Lingyan Feng[1], Fang Zheng[2], Feili Gong[2], Hanju Huang[3], Binlian Sun[1]✉

1. Medical College, Jianghan University, Wuhan 430056, China
2. Department of Immunology, School of Basic Medicine, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China.
3. Department of Pathogen Biology, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China.

Supplementary Table S1. Frequency of *KIR* genes in HCV and healthy patients

KIR Gene	KIR Gene Carrier Frequency		*P* Value	Odds Ratio(95% CI)
	HCV Patients Observed/N (%)	Healthy controls Observed/N (%)		
KIR2DL1	331/333 (99.4)	316/320 (98.75)	0.385	2.095 (0.381–11.518)
KIR2DL2	186/333 (55.86)	94/320 (29.38)	< 0.001	3.042 (2.201–4.204)
KIR2DL3	329/333 (98.80)	319/320 (99.69)	0.193	0.258 (0.029–2.319)
KIR2DL4	333/333 (100.00)	320/320 (100.00)	Not analyzed	
KIR2DL5	146/333 (43.84)	142/320 (44.38)	0.891	0.979 (0.719–1.333)
KIR3DL1	327/333 (98.20)	312/320 (97.50)	0.538	1.397 (0.479–4.073)
KIR3DL2	333/333 (100.00)	320/320 (100.00)	Not analyzed	
KIR3DL3	333/333 (100.00)	320/320 (100.00)	Not analyzed	
KIR2DS1	127/333 (38.14)	116/320 (36.25)	0.618	1.084 (0.789–1.489)
KIR2DS2	101/333 (30.33)	88/320 (27.50)	0.425	1.148 (0.818–1.611)
KIR2DS3	107/333 (32.13)	77/320 (24.06)	0.022	1.494 (1.059–2.108)
KIR2DS4	173/333 (51.95)	281/320 (87.81)	< 0.001	0.150 (0.101–0.223)
KIR2DS5	76/333 (22.82)	71/320 (22.19)	0.846	1.037 (0.718–1.498)
KIR3DS1	137/333 (41.14)	117/320 (36.56)	0.230	1.213 (0.885–1.662)
KIR2DP1	333/333 (100.00)	320/320 (100.00)	Not analyzed	
KIR3DP1	333/333 (100.00)	320/320 (100.00)	Not analyzed	

Supplementary Table S2. Frequency of *KIR* genes in NR and SVR HCV patients

| KIR Gene | KIR Gene Carrier Frequency | | P Value | Odds Ratio (95% CI) |
	NR Patients Observed/N (%)	SVR Patients Observed/N (%)		
KIR2DL1	35/36 (97.22)	61/62 (98.39)	0.694	0.574 (0.035–9.462)
KIR2DL2	26/36 (72.22)	32/62 (51.61)	0.045	2.438 (1.008–5.895)
KIR2DL3	35/36 (97.22)	62/62 (100.00)	0.187	0.972 (0.920–1.027)
KIR2DL4	36/36 (100.00)	62/62 (100.00)	Not analyzed	
KIR2DL5	12/36 (33.33)	24/62 (38.71)	0.595	0.792 (0.335–1.873)
KIR3DL1	35/36 (97.22)	61/62 (98.39)	0.694	0.574 (0.035-9.462)
KIR3DL2	36/36 (100.00)	62/62 (100.00)	Not analyzed	
KIR3DL3	36/36 (100.00)	62/62 (100.00)	Not analyzed	
KIR2DS1	12/36 (33.33)	25/62 (40.32)	0.491	0.740 (0.313–1.747)
KIR2DS2	8/36 (22.22)	16/62 (25.81)	0.691	0.821 (0.311–2.167)
KIR2DS3	9/36 (25.00)	17/62 (27.42)	0.794	0.882 (0.345–2.255)
KIR2DS4	32/36 (88.89)	61/62 (98.39)	0.039	0.131 (0.014–1.223)
KIR2DS5	10/36 (27.78)	21/62 (33.87)	0.532	0.751 (0.306–1.845)
KIR3DS1	17/36 (47.22)	30/62 (48.39)	0.911	0.954 (0.419–2.172)
KIR2DP1	36/36 (100.00)	62/62 (100.00)	Not analyzed	
KIR3DP1	36/36 (100.00)	62/62 (100.00)	Not analyzed	

Supplementary Table S3. Meta-analysis of the occurrence of KIR2DL2 in NR and SVR HCV patients

| First Author | Year | Source | NR | | SVR | | Weight (%) | Odds Ratio (95% CI)[a] M-H, Fixed |
			KIR2DL2+	Total	KIR2DL2+	Total		
Carneiro	2010	*Liver international*	43	101	23	66	0.149	1.39 (0.73, 2.63)
Vidal-Castineira	2010	*JVI*	84	154	83	218	0.257	1.95 (1.28, 2.97)
Dring	2011	*PNAS*	73	155	57	118	0.221	0.95 (0.59, 1.54)
De Vasconcelos	2013	*GMB*	22	26	16	17	0.016	0.34 (0.04, 3.37)
Vidal-Castineira	2014	*Plos One*	323	498	172	313	0.357	1.51 (1.13, 2.02)
Total (95% CI)				934		732	1	1.41 (1.05, 1.88)
Total events			545		351			

Heterogeneity: Chi² = 6.51, df = 4 (P = 0.16); I² = 39%

Test for overall effect: Z = 3.59 (P = 0.0003)

a：a significant association of *KIR2DL2* gene with no response to therapy was detected under the Mantel-Haenszel test (M-H) of fixed effect model.

Supplementary Figure S1. Funnel plot analysis to detect
publication bias using Egger's linear regression test